Back to User profile » Dr Pei-Jian Peng
Papers published by Dr Pei-Jian Peng:
CD47 Overexpression Is Associated with Epstein–Barr Virus Infection and Poor Prognosis in Patients with Nasopharyngeal Carcinoma
Wang ZH, Pei XF, Zhu ZQ, Lin Z, Mao YY, Xu XL, Luo YL, Zhang L, Peng PJ
OncoTargets and Therapy 2020, 13:3325-3334
Published Date: 21 April 2020
Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
Lin Z, Lv WZ, Wang SY, Zou JL, Con YY, Wang ZH, Xiao M, Peng PJ
Cancer Management and Research 2017, 9:671-677
Published Date: 20 November 2017
Everolimus enhances cellular cytotoxicity of lapatinib via the eukaryotic elongation factor-2 kinase pathway in nasopharyngeal carcinoma cells
Liu L, Wang ZH, Han J, Tang C, Chen N, Lin Z, Peng PJ
OncoTargets and Therapy 2016, 9:6195-6201
Published Date: 11 October 2016
Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma
Peng PJ, Lv BJ, Tang C, Liao H, Lin Z, Liu YM, Wang ZH, Wang SY, Cheng ZB
Drug Design, Development and Therapy 2015, 9:6401-6405
Published Date: 10 December 2015
Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis
Peng PJ, Cheng H, Ou XQ, Zeng LJ, Wu X, Liu YM, Lin Z, Tang YN, Wang SY, Zhang HY, Chen ZB
Drug Design, Development and Therapy 2014, 8:1083-1087
Published Date: 14 August 2014